天津武清龙济医院泌尿专科医院怎么样(天津市龙济男科医院收费怎么样) (今日更新中)

The city is opening a code enforcement investigation into an apartment complex that is made up almost entirely of short-term vacation rentals.The complex, called The Louisiana, is on University Avenue in North Park. A company called Sonder has leased each of its 13 market-rate apartments to rent to visitors (the complex has two affordable units as well). A one-bedroom apartment is listed at 0 per night for a weekend in October. The city made the call after a group called Save San Diego Neighborhoods held a press conference outside the complex Thursday.Board member Brian Curry said this type of business is contributing to the city's supply crunch that pushes up rents. He also questioned whether the complex, permitted as mixed-use apartments, is allowed to be operated more like a hotel. "It is simply wrong to steal housing from our residents to meet the visitor room night demand," said Curry. In a statement before the city announced its investigation, Sonder defended its arrangement with the developer. "Sonder San Diego strictly complies with all local laws and pays all local taxes, period. Contrary to recent false claims, our location on University Avenue is fully licensed, legal and not zoned ‘residential' but for commercial and mixed-use with visitor accommodation allowed by right," the statement said. "We look forward to continuing to grow and give back in San Diego while working with the City on real solutions for affordable housing.”Additionally, the buildings developer said the extra funds from the lease with Sonder is helping to fund other housing construction faster. Councilwoman Barbara Bry, who attended Thursday's news conference, said the city can't build its way out of its housing crisis without addressing the proliferation of short-term rentals. 10News has reached out to Sonder for comment on the city investigation. 1871

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201

The COVID-19 pandemic has been forcing millions of Americans to work and learn from home for several months at this point.But while working and learning from home may be routine, that hasn't made it any easier — meetings are still being sabotaged with rambunctious pets, unreliable WiFi signals and barely-clothed family members.Then, there's the dreaded mute button. Failing to click it (or mistakenly turning it off) has sunk many a meeting in the last five months.And apparently, U.S. senators aren't immune to mute-button woes.During the Senate Committee on Homeland Security and Governmental Affairs' questioning of Postmaster General Louis DeJoy on Friday, Chairman Ron Johnson (R-Wisconsin) recognized Sen. Tom Carper (D-Delware) for questioning. After a few moments, Carper didn't respond, and Johnson moved on to Sen. James Lankford (D-Michigan).Apparently, Carper was at his computer but muted. And when audio was restored to his microphone, it caught the senator frustratingly releasing a series of expletives.Johnson asked if Carper was able to unmute his laptop, adding "we don't want to be on TV again," with a laugh.Following the snafu, Carper was able to conduct his questioning.Later, Carper joked about the incident on Twitter."Those who know me know that there are few things that get me more fired up than protecting the Postal Service! #DontMessWithUSPS," he tweeted. 1396

The creator of Jelly Belly is diving into a new brand of the iconic candy. According to Business Insider, Jelly Belly inventor David Klein is launching Spectrum Confections, which will sell CBD-infused jelly beans. Business Insider reports that the candies will come in 38 flavors, including pi?a colada, strawberry cheesecake and roasted marshmallow. Each bean will reportedly contain 10 milligrams of CBD. Jelly Belly itself, which was created by Klein in the 70s, isn’t involved in the new creation. CBD is the non-psychoactive component of marijuana used for treating pain and inflammation, according to Medical News Today. 636

The CDC says there's yet another illness that you need to be aware of; one that has serious outcomes as doctors warn of a possible outbreak of AFM, or Acute Flaccid Myelitis, which can cause paralysis in children.When Kinley was just 5 years old, what started as a stomach and headache turned into exhaustion. By the time her parents got her to the hospital, she was admitted into the ICU. By the next morning, she was on life support and paralyzed in all limbs.Now 11, hers is one of the 633 nationwide cases to date of AFM. Dr. Janell Routh, a pediatrician and AFM Team Leader for the CDC, says they've been tracking the neurologic condition since 2014.“Something changed in 2014, the epidemiology changed and we saw an increase in cases,” Routh said. “We confirmed 120 cases in 2014. We think that new epidemiology suggests that we have either a new cause for this condition or a cause that somehow changed to become more virulent.”By 2018, the number of cases had doubled. Which means 2020, the year that seems to be affected by everything, will see more cases. The CDC says the type of virus that causes AFM starts with a basic fever. Which then may go away and come back.“Most parents don’t necessarily think much about a fever and the sniffles- if parents do see limb weakness so their child complaining of pain maybe headache or back pain and weakness in one or more limbs that is a sign they need to seek medical care immediately,” Routh said.Routh says AFM progresses rapidly by attacking the gray matter of the spinal cord. Paralysis can set in in a matter of hours or days.“I remember one mother telling me that her child laid limply on her chest, couldn’t move. Those are signs that they really need to call their pediatrician or go the ER and get evaluated,” Routh said.As it's a relatively new syndrome, there's a lot we don't know. There's no lab test to diagnose it and there's no vaccine. 90% of the cases are in children under the age of 18 with the average age being 5. Some recover, some have long term complications like Kinley, who is now 11 and still on a ventilator. She's regained use of her right leg and foot and uses it for school work and painting.“I’ve definitely seen how this condition can affect children and their families, not just from a physical standpoint but from an emotional standpoint disrupting the lives of families,” Routh said.The CDC is now trying to track patients and outcomes, tracking the recovery of those who have been diagnosed and researching those who may be at risk. They do know that it seems to affect kids in late August and early September, and prevention is similar to what you'd do for other viruses like COVID-19. Hand washing, staying home if you're sick, and having good cough etiquette.“AFM is a medical emergency and so if parents do see signs of limb weakness in their children after a viral illness and in those late summer early fall months - call your pediatrician go to the emergency room,” Routh said.And she says, while there is so much focus on COVID-19, it's definitely not the only virus that is spreading. 3093

来源：资阳报